AU2001235844A1 - Imidazol-2-carboxamide derivatives as raf kinase inhibitors - Google Patents

Imidazol-2-carboxamide derivatives as raf kinase inhibitors

Info

Publication number
AU2001235844A1
AU2001235844A1 AU2001235844A AU3584401A AU2001235844A1 AU 2001235844 A1 AU2001235844 A1 AU 2001235844A1 AU 2001235844 A AU2001235844 A AU 2001235844A AU 3584401 A AU3584401 A AU 3584401A AU 2001235844 A1 AU2001235844 A1 AU 2001235844A1
Authority
AU
Australia
Prior art keywords
sub
sup
alkyl
hydrogen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235844A
Other languages
English (en)
Inventor
Alessandra Gaiba
Andrew Kenneth Takle
David Matthew Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2001235844A1 publication Critical patent/AU2001235844A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001235844A 2000-03-06 2001-03-02 Imidazol-2-carboxamide derivatives as raf kinase inhibitors Abandoned AU2001235844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0005357.9A GB0005357D0 (en) 2000-03-06 2000-03-06 Compounds
GB0005357 2000-03-06
PCT/GB2001/000916 WO2001066540A1 (en) 2000-03-06 2001-03-02 Imidazol-2-carboxamide derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001235844A1 true AU2001235844A1 (en) 2001-09-17

Family

ID=9887051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001235844A Abandoned AU2001235844A1 (en) 2000-03-06 2001-03-02 Imidazol-2-carboxamide derivatives as raf kinase inhibitors

Country Status (12)

Country Link
US (1) US6987119B2 (de)
EP (1) EP1261602B1 (de)
JP (1) JP2003525937A (de)
AT (1) ATE266021T1 (de)
AU (1) AU2001235844A1 (de)
DE (1) DE60103133T2 (de)
DK (1) DK1261602T3 (de)
ES (1) ES2217118T3 (de)
GB (1) GB0005357D0 (de)
PT (1) PT1261602E (de)
TR (1) TR200401903T4 (de)
WO (1) WO2001066540A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (de) 1999-01-13 2011-12-28 Bayer HealthCare LLC GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BR0015532A (pt) * 1999-11-22 2002-06-25 Smithkline Beecham Plc Compostos
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
US20040192689A1 (en) * 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121494D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1478358B1 (de) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib Tosylate zur Behandlung von durch unnormale Angiogenese gekennzeichneten Krankheiten
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
CA2497240A1 (en) 2002-08-29 2004-03-11 Andrew Asher Protter Methods of promoting osteogenesis
CA2526636C (en) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
KR20070048798A (ko) * 2004-08-31 2007-05-09 아스트라제네카 아베 퀴나졸리논 유도체 및 이것의 ｂ-ｒａｆ 억제제로서의 용도
WO2006024836A1 (en) * 2004-09-01 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
CA2626623C (en) * 2005-10-18 2016-08-30 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016070B1 (de) * 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitoren von c-fms-kinase
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
EP2184285B1 (de) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und ihre verwendung
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
MX2019003095A (es) 2016-09-19 2019-07-04 Novartis Ag Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk.
PT3618875T (pt) 2017-05-02 2023-08-07 Novartis Ag Terapia de combinação que compreende um inibidor de raf e trametinib

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75287B (de) 1980-07-25 1984-07-13 Ciba Geigy Ag
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
WO1997012876A1 (en) * 1995-10-06 1997-04-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AU727939B2 (en) 1996-04-03 2001-01-04 Merck & Co., Inc. A method of treating cancer
AU708883B2 (en) 1996-06-10 1999-08-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
ES2224222T3 (es) 1996-10-15 2005-03-01 G.D. Searle Llc Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de neoplasias.
JP2002515915A (ja) 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 炎症性疾患の治療で有用な２−置換イミダゾール類
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
ES2153809T3 (es) * 1997-12-22 2005-07-16 Bayer Pharmaceuticals Corporation Inhibicion de la cinasa raf por uso de difnil-ureas sustituidas simetrica y asimetricamente.
JP2002516322A (ja) 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規２−アルキル置換イミダゾール化合物
BR0015532A (pt) 1999-11-22 2002-06-25 Smithkline Beecham Plc Compostos
AU2002236476A1 (en) 2000-11-20 2002-05-27 Smith Kline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
WO2001066540A1 (en) 2001-09-13
JP2003525937A (ja) 2003-09-02
DK1261602T3 (da) 2004-08-30
GB0005357D0 (en) 2000-04-26
EP1261602A1 (de) 2002-12-04
ES2217118T3 (es) 2004-11-01
PT1261602E (pt) 2004-08-31
US20030134837A1 (en) 2003-07-17
EP1261602B1 (de) 2004-05-06
TR200401903T4 (tr) 2004-09-21
DE60103133D1 (de) 2004-06-09
ATE266021T1 (de) 2004-05-15
US6987119B2 (en) 2006-01-17
DE60103133T2 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
AU2001235844A1 (en) Imidazol-2-carboxamide derivatives as raf kinase inhibitors
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
EP1724262A4 (de) 1-(2h)-isochinolonderivat
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
SE0202463D0 (sv) Novel compounds
TNSN03110A1 (en) Azaindoles.
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
NO20082101L (no) Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
NO20015447D0 (no) Kinolinderivater som inhibitorer av MEK enzymer
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
RU2007110629A (ru) Ингибиторы днк-пк
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
WO2021012049A8 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
UA74341C2 (uk) Похідні борелідину, які інгібують ангіогенез
IS7911A (is) Ímídasólafleiður með sækni í alfa 2 viðtakavirkni
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
NO20101256L (no) Azaindoler
ECSP993005A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.